The current pharmacological landscape of tuberculous meningitis: Where to next?

Expert Review of Clinical Pharmacology

Volumn 9, Issue 5, 2016, Pages 625-627

  Mai, Nguyen Thi Hoang ^a,b   Thwaites, Guy E ^b,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; LEUKOTRIENE A4 HYDROLASE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BLOOD BRAIN BARRIER; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; EDITORIAL; GRANULOMATOUS INFLAMMATION; HUMAN; HYDROCEPHALUS; LUNG TUBERCULOSIS; MENINGOENCEPHALITIS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT RESPONSE; TUBERCULOUS MENINGITIS; MICROBIOLOGY; PATHOLOGY; TUBERCULOSIS, MENINGEAL;

ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, MENINGEAL;

EID: 84961215664     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1155447     Document Type: Editorial

References (16)

1. World Health Organization. Global tuberculosis report. Geneva: WHO; 2014
2. Thwaites GE, Van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013; 12 (10): 999-1010
3. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis. 2010; 90 (6): 375-392
4. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010; 90 (5): 279-292
5. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis. 1993; 148 (3): 650-655
6. Donald PR, Schoeman JF, Van Zyl LE, et al. Intensive short course chemotherapy in the management of tuberculous meningitis. Int J Tuberc & Lung Dis. 1998; 2 (9): 704-711
7. Van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014; 33 (3): 248-252
8. Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191 (9): 1058-1065
9. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013; 13 (1): 27-35
10. Heemskerk D, Day J, Chau TT, et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011; 12: 25
11. Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016; 374 (2): 124-134
12. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 2010; 293 (1-2): 12-17
13. Schoeman JF. Janse van Rensburg A, Laubscher JA, Springer P. The role of aspirin in childhood tuberculous meningitis. J Child Neurol. 2011; 26 (8): 956-962
14. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004; 351 (17): 1741-1751
15. Simmons CP, Thwaites GE, Quyen NT, et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol. 2005; 175 (1): 579-590
16. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012; 148 (3): 434-446